1. Clinical Overview
Molecule: First-in-class dual incretin agonist targeting GIP + GLP-1 receptors
FDA Approved: Type 2 Diabetes (Mounjaro®) • Chronic Weight Management (Zepbound®)
Classification: Dual incretin • Anti-obesity • Appetite/reward suppression • Glucose-normalizing • Cardiometabolic optimization
Clinical Potency: 15–22% total body weight loss. Superior A1C, lipid, BP improvements.
2. Mechanisms of Action
2.1 GIP Receptor Agonism (Primary Differentiator)
Improved insulin secretion/sensitivity, reduced GLP-1-associated nausea, additive weight-loss synergy, hypothalamic food-reward reduction. More tolerable and potent than GLP-1 alone.
2.2 GLP-1 Receptor Agonism
Appetite suppression, delayed gastric emptying, reduced cravings/caloric intake, lower postprandial glucagon/glucose.
2.3 Dual-Incretin Synergy
GIP + GLP-1 together: multiplicative weight loss, stronger metabolic improvements, higher insulin sensitivity, lower GI side effects, improved energy expenditure. Faster and larger results than semaglutide.
3. Clinical Applications
3.1 Obesity
15–22% body weight loss. Waist circumference, visceral fat. BMI ≥30 or ≥27 with comorbidities. GLP-1 non-responders, post-semaglutide plateau.
3.2 Type 2 Diabetes
HbA1c reduction 2.5–3.0%. Remission in select patients. Lower fasting insulin, improved beta-cell sensitivity. Superior to semaglutide.
3.3 Metabolic Syndrome
Fasting glucose/insulin, HOMA-IR, lipids, blood pressure. Cardiometabolic restoration.
3.4 NAFLD / NASH
Reduced liver fat, improved ALT/AST, lower fibrosis, reduced central adiposity.
3.5 GLP-1 Plateau
Semaglutide plateau, insufficient appetite suppression, poor reward regulation.
4. Administration & Protocols
| Period | Dose |
|---|
| Weeks 1–4 | 2.5 mg weekly |
| Weeks 5–8 | 5 mg weekly |
| Weeks 9–12 | 7.5 mg weekly |
| Weeks 13–16 | 10 mg weekly |
| Weeks 17–20 | 12.5 mg weekly |
| Week 21+ | 15 mg weekly (max) |
Moderate obesity: 7.5–10 mg. Severe: 10–15 mg. Plateau: +2.5 mg increments. Maintenance: 2.5–5 mg or biweekly.
Route: SC (arm, thigh, abdomen). Same day weekly. Rotate sites. No fasting required.
5. Combination Therapy (Peptide Protocol Portal Synergy)
+ Cagrilintide: Most potent appetite synergy — severe obesity, emotional/sugar-reward eating
+ SLU-PP-332: Mitochondrial, UCP-1 thermogenesis, fat oxidation — accelerated recomposition
+ AOD-9604: Stubborn lower abdominal, gluteofemoral, visceral fat
+ Tesofensine: Hedonic hunger — dopamine, cravings, reward regulation
+ MOTS-c / SS-31: Exercise fatigue, mitochondrial dysfunction, metabolic burnout
6. Clinical Decision Trees
Tree 1 — Is Tirzepatide Indicated?
BMI >30 or >27 + comorbidities? → YES
T2DM requiring A1C reduction? → YES
Plateau on semaglutide? → YES
Pancreatitis history? → CAUTION
Severe GI motility disorder? → AVOID
Tree 2 — Dose Escalation
Poor appetite control? → Increase 2.5 mg
GI side effects? → Maintain current
Near goal weight? → Reduce to 2.5–5 mg
Athlete/recomposition? → Maintain 5–7.5 mg
7. Integrated Archetypes
A — High-Impact Fat Loss
Tirzepatide 10–15 mg/wk + SLU-PP-332 + AOD-9604 + MOTS-c weekly
Outcome: Aggressive, rapid fat reduction.
B — Diabetes Optimization
Tirzepatide 5–10 mg/wk + metformin/berberine + Omega-3 + cardiometabolic diet
Outcome: A1C normalization, insulin sensitivity restoration.
C — Appetite Control & Reward Reset
Tirzepatide 5–10 mg + Tesofensine + Cagrilintide (if needed)
Outcome: Elimination of binge-eating patterns.
D — Weight-Loss Maintenance
Tirzepatide 2.5–5 mg/wk + exercise + AOD-9604 + NAD+ metabolic support
Outcome: Stable weight, minimal rebound.
8. Expected Timeline
Week 1–3: Appetite/cravings decrease
Week 4–8: 3–8% body weight reduction
Month 3–6: 10–15% reduction
Month 6–12: Up to 20%+ reduction
Long-term: Improved metabolic health, reduced cardiometabolic risk
9. Contraindications
Absolute
- Personal/family MTC history
- MEN2 syndrome
- Pregnancy / Breastfeeding
Relative
- Gastroparesis
- Pancreatitis history
- Gallbladder disease
- Severe GERD
- Renal impairment
10. Adverse Effects
Common: Nausea, vomiting, diarrhea/constipation, fatigue, bloating. Less common: Gallbladder complications, pancreatitis (rare), dehydration-related kidney injury. Rare: Hypoglycemia (with insulin/SUs), severe GI motility issues.
11. Monitoring
- Weight & waist circumference
- A1C & fasting glucose
- Lipid panel
- Kidney function
- Gallbladder symptoms
- Hydration & appetite patterns
- Reduce insulin/SU doses if diabetic
Legal Disclaimer
This document is provided solely for educational and informational purposes. Tirzepatide and other peptides referenced herein may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.
References — Tirzepatide
Foundational Incretin Biology
1. Drucker, D. J. GLP-1, GIP metabolic regulation. Cell Metabolism, 27(4), 740–756 (2018).
2. Nauck, M. A., & Meier, J. J. GIP–GLP-1 synergy. Lancet Diabetes Endocrinol, 4(5), 473–482 (2016).
3. Holst, J. J., & Rosenkilde, M. M. GIP/GLP-1 receptor physiology. Physiol Rev, 100(4), 1427–1468 (2020).
4. Samms, R. J., et al. Dual incretin glucose/energy homeostasis. Diabetes, 65(6), 1651–1661 (2016).
Development & Preclinical
5. Frias, J. P., et al. First-in-human LY3298176. Lancet, 392(10160), 2180–2193 (2018).
6. Finan, B., et al. Co-agonist combinatorial signaling. Nat Med, 29(2), 276–284 (2017).
7. Coskun, T., et al. Dual receptor mechanistic basis. Sci Transl Med, 14(671), eabk3442 (2022).
8. Samms, R. J., et al. Thermogenic/metabolic remodeling. Cell Metabolism, 34(4), 573–589 (2022).
SURPASS Trials — T2DM
9. Frias, J. P., et al. SURPASS-1 monotherapy. NEJM, 385(6), 503–515 (2021).
10. Ludvik, B., et al. SURPASS-2 vs semaglutide. NEJM, 385(6), 503–515 (2021).
11. Dahl, D., et al. SURPASS-3 vs insulin degludec. Lancet, 398(10300), 583–598 (2021).
12. Del Prato, S., et al. SURPASS-4 high CV risk. Lancet, 398(10313), 1811–1824 (2021).
13. Ludvik, B., et al. SURPASS-5 + insulin glargine. Diabetes Care, 45(1), 69–77 (2022).
14. Sattar, N., et al. SURPASS-CVOT rationale. Diabetes Obes Metab, 23(11), 2307–2316 (2021).
SURMOUNT Trials — Obesity
15. Jastreboff, A. M., et al. SURMOUNT-1 landmark Phase 3. NEJM, 387, 205–216 (2022).
16. Garvey, W. T., et al. SURMOUNT-2 obese + T2DM. Lancet, 401(10380), 2032–2046 (2023).
17. Wharton, S., et al. SURMOUNT-3 post-lifestyle. Nat Med, 29(10), 1802–1811 (2023).
18. Aronne, L. J., et al. SURMOUNT-4 sustainability. Lancet, 402(10389), 1428–1440 (2023).
Cardiometabolic & Lipid
19. Heise, T., et al. Insulin sensitivity/β-cell. Diabetes Care, 45(3), 641–650 (2022).
20. Sattar, N., et al. Lipids, BP, inflammation. Lancet Diabetes Endocrinol, 10(8), 589–599 (2022).
21. Gastaldelli, A., et al. Liver fat/hepatic insulin. Diabetes Care, 44(9), 2098–2106 (2021).
22. Han, J., et al. Visceral fat/hepatic lipid. Diabetes Obes Metab, 24(6), 1028–1036 (2022).
NAFLD / NASH
23. Kuchay, M. S., et al. Liver fat/metabolic markers. Lancet Gastroenterol Hepatol, 7(11), 983–993 (2022).
24. Rinella, M. E., et al. Dual agonists & NASH. Nat Rev Gastroenterol Hepatol, 19, 187–205 (2022).
Renal
25. Vaduganathan, M., et al. eGFR/renal biomarkers. Lancet Diabetes Endocrinol, 11(1), 17–28 (2023).
26. Thomas, M. C. Renal protection potential. Kidney Int, 103(4), 690–700 (2023).
Safety
27. Frias, J. P., et al. SURPASS safety profile. NEJM, 385, 503–515 (2021).
28. Ludvik, B., et al. Adverse event profiling. Diabetes Care, 45, 69–77 (2022).
29. FDA CDER. Mounjaro™/Zepbound™ approval/safety. FDA, 2022–2024.
Comparative
30. Frías, J. P., et al. vs semaglutide/dulaglutide/SGLT2i. NEJM, 385(6), 503–515 (2021).
31. Nauck, M. A., et al. Dual vs GLP-1-only. Diabetes Obes Metab, 25(S1), 3–17 (2023).
32. Perakakis, N., et al. Metabolic polyagonists evolution. Nat Rev Endocrinol, 18, 765–784 (2022).